Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

被引:0
|
作者
Gebbia, V
Mauceri, G
Testa, A
Tirrito, M
Varvara, F
Cucchiara, A
Borsellino, N
Girlando, A
Ferrara, M
Caruso, F
机构
[1] Ctr Catanese Oncol, Div Med Oncol, I-95100 Catania, Italy
[2] Clin Macchiarella, Div Oncol, Palermo, Italy
[3] Clin Torina, Serv Oncol, Palermo, Italy
[4] Ctr Catanese Oncol, Div Radiotherapy, Catania, Italy
[5] Ctr Catanese Oncol, Div Surg Oncol, I-95100 Catania, Italy
关键词
breast cancer; metastases; 5-fluorouracil; levofolinic acid; vinorelbine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-four consecutive patients with metastatic breast carcirioma (MBC) refractory to first line chemotherapy 2 were treated with high-dose folinic acid (FA) 100 mg/m(2) diluted in 250 cc of normal saline as 2 2 hour infusion followed by 5-fluorouracil (5FU) 400 mg/m(2) bolus then 5FU 600 mg/m(2) as continuous infusion for 22 hours. This therapy was repeated for 2 consecutive days. Chemotherapy was repeated every 15 days. All enrolled patients were evaluable for objective response. A complete response was achieved in 1 patient (4%) and a partial response in 6 cases (25%) for an overall response rate of 29% (confidence limits 18%-39%). The median duration of objective responses was 8.4+ months (range 3.0+/12.8). Six patients showed no change (25%) with a median duration of 4.0 months 11 patients progressed (46%). A subjective improvemernt in tumor-related symptoms was reported by all responding patients and in 3 patients with no change. Most patients (7/10) with symptomatic bone lesions had a subjective improvement with reduction in analgesic drugs consumption. Objective responses were observed at all sites of disease. In fact, responses were seen in the skin liver lung bore and rodal metastases. The median overall survival was 13.0+ months (range 4.0/16.2+). Over a total of 160 cycles (a mean of 6.6 cycles/patient) grade 1-2 leukopenia was seen in 9 patients (37%) grade 1 thrombocytoperia in 4 patients (17%) and grade 1 anemia in only 2 cases (8%). Grade 3-4 leukopenia or thrombocytopenia were not seen. Phlebitis at the injection vein occurred in 3/10 patients (30%) which refuded to implant a central line. In patients with a central line or a port-a-cath no cases of vascula toxicity were seen. Gastrointestinal toxicity was very mild with 9 patients (37%) suffering from grade 1- 2 nausea/vomiting 6 patients (25%) complaining of grade 1-2 diarrhea and 6 patients with grade 1-2 stomatitis. Hand-foot syndrome was observed in only 1 patient. No cases of grade 3-4 gastrointestinal toxicities have been, observed No cases of cardiotoxicity and/or neurotoxicity were recorded The combination of high-dose FA and 5FU given as 48 hour continuous venous infusion every 2 weeks is active, at least in. terms of objective response rate and tumor related symptoms palliation against anthracycline-refractory MBC These results compare favorably with bolus administration of FA and 5FU or other salvage regimens.
引用
收藏
页码:2289 / 2292
页数:4
相关论文
共 50 条
  • [41] Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma
    Gebbia, V
    Testa, A
    Majello, E
    Cannata, G
    Tirrito, ML
    Mastrandrea, G
    Feo, M
    Bajardi, G
    Colucci, G
    Gebbia, N
    ANTI-CANCER DRUGS, 1996, 7 (04) : 386 - 391
  • [42] Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
    Mehta, VK
    Fisher, GA
    Ford, JM
    Oberhelman, HA
    Vierra, MA
    Bastidas, AJ
    Poen, JC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (05): : 1483 - 1487
  • [43] Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: A phase I-II study
    Oliani, C
    Padovani, M
    Manno, P
    Barana, D
    Falconi, M
    Bassi, C
    Cavallini, G
    Pederzoli, P
    Cetto, GL
    ANTICANCER RESEARCH, 2004, 24 (3B) : 2107 - 2112
  • [44] A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
    Ikeda, M
    Okusaka, T
    Ueno, H
    Takezako, Y
    Morizane, C
    CANCER, 2005, 103 (04) : 756 - 762
  • [45] Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer
    Baoli Qin
    Ken Kato
    Kenji Mitsugi
    Minoru Nakamura
    Risa Tanaka
    Eishi Baba
    Hiroshi Ariyama
    Toshiro Kuroiwa
    Mine Harada
    Shuji Nakano
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 114 - 119
  • [46] A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin refractory metastatic bladder cancer
    Huan, SD
    Aitken, SE
    Stewart, DJ
    ANNALS OF ONCOLOGY, 1995, 6 (08) : 836 - 837
  • [47] Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer
    Qin, BL
    Kato, K
    Mitsugi, K
    Nakamura, M
    Tanaka, R
    Baba, E
    Ariyama, H
    Kuroiwa, T
    Harada, M
    Nakano, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 114 - 119
  • [48] A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
    Caponigro, F
    Comella, P
    Marcolin, P
    Spena, FR
    Biglietto, M
    Cartenì, G
    De Lucia, L
    Avallone, A
    Gravina, A
    Comella, G
    CANCER, 1999, 85 (04) : 952 - 959
  • [49] Nocturnal 5-fluorouracil infusion to patients with breast cancer prior to surgery: Appearance of 5-fluorouracil-induced AgNORs aggregation (FAA)
    Furuya, Y
    Yamamoto, K
    Kohno, N
    Yamamoto, M
    Saitoh, Y
    CANCER LETTERS, 1997, 116 (01) : 79 - 84
  • [50] A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
    Ando, M
    Watanabe, T
    Sasaki, Y
    Ying, DF
    Omuro, Y
    Katsumata, N
    Narabayashi, M
    Tokue, Y
    Fujii, H
    Igarashi, T
    Wakita, H
    Ohtsu, T
    Itoh, K
    Adachi, I
    Taguchi, T
    BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1937 - 1943